Monday, November 8, 2021

Immunotherapy-chemotherapy treatment coupled with in-depth genomic analyses leads to improved survival for patients with mesothelioma

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial.

from Top Health News -- ScienceDaily https://ift.tt/3mVBwd3
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

JWST spots a strange red dot so extreme scientists can’t explain it

The discovery of strange, ultra-red objects—especially the extreme case known as The Cliff—has pushed astronomers to propose an entirely new...